Investigational drug · Phase 2
BPC-2001
Also called: KRN-7000
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BPC-2001"
First trial start
2025
Oct 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BPC-2001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Graft -Versus-host-disease
- aGVHD
- Haploidentical Stem Cell Transplantation
- cGVHD
Largest trials
Live from ClinicalTrials.gov: studies naming "BPC-2001" as an intervention, largest first.
BioPhoenix Co., Ltd.Industry
NCT07246031 · 50 participants (planned) · Start Oct 29, 2025 · Primary completion Apr 30, 2028
Drug: BPC-2001 · For: Graft -Versus-host-disease; aGVHD; Haploidentical Stem Cell Transplantation and 1 more
Sites: Beijing, China; Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development.
Yang D, Luo X, Lian Q, et al. · Acta Pharm Sin B 2022
- Optical Control of Cytokine Production Using Photoswitchable Galactosylceramides.
Hartrampf N, Seki T, Baumann A, et al. · Chemistry 2020
- Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation.
Longet S, Aversa V, O'Donnell D, et al. · Int J Pharm 2017
- Synthesis and biological activities of C-glycosides of KRN 7000 with novel ceramide residues.
Altiti AS, Ma X, Zhang L, et al. · Carbohydr Res 2017
- A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens.
Davitt CJ, McNeela EA, Longet S, et al. · J Control Release 2016
- The stimulating adventure of KRN 7000.
Banchet-Cadeddu A, Hénon E, Dauchez M, et al. · Org Biomol Chem 2011
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.